Drug intelligence / Profile preview

DTPA-AMB8LK

Development stage: Preclinical
Lead developer: Mablife
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DTPA-AMB8LK is a preclinical chelator-antibody conjugate comprising the anti-ferritin monoclonal antibody AMB8LK linked to benzyl-diethylenetriaminepentaacetic acid. The antibody recognizes human ferritin, including tumor-associated H-ferritin, which is overexpressed in pancreatic adenocarcinoma. The DTPA chelator enables radiolabeling with indium-111 for SPECT imaging or yttrium-90 for targeted radioimmunotherapy. In CAPAN-1 pancreatic adenocarcinoma xenograft models, radiolabeled Bz-DTPA-AMB8LK demonstrated tumor localization and was proposed as a candidate for further therapeutic evaluation. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK23191/))

Other names: Bz-DTPA-AMB8LKBz-DTPA-AMB-8LKBz-DTPA-AMB 8LK

Beyond the preview

Go deeper on DTPA-AMB8LK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTPA-AMB8LK.

Explore the full profile